Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.58 |
| ▸ | AR | P10275 | 4/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.56 |
| ▸ | BTK | Q06187 | 4/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24420981 | 1.00 | CRBN (0.58) | CRBNARDDB1BTKIRAK1 | |
| SCHEMBL30726298 | 0.94 | CRBN (0.56) | CRBNARDDB1BTKIRAK1 | |
| SCHEMBL27040208 | 0.94 | CRBN (0.56) | CRBNARDDB1BTKIRAK1 | |
| SCHEMBL23173248 | 0.93 | CRBN (0.64) | CRBNARDDB1 | |
| SCHEMBL26814139 | 0.91 | CRBN (0.57) | CRBNARDDB1IRAK1IRAK4 | |
| SCHEMBL25368697 | 0.88 | CRBN (0.60) | CRBNARDDB1BTKIRAK1 | |
| SCHEMBL26928955 | 0.88 | CRBN (0.60) | CRBNARDDB1BTKIRAK1 | |
| SCHEMBL30693000 | 0.88 | CRBN (0.60) | CRBNARDDB1BTKIRAK1 | |
| SCHEMBL30135995 | 0.88 | CRBN (0.56) | CRBNARDDB1BTKIRAK1 | |
| SCHEMBL26814212 | 0.87 | CRBN (0.55) | CRBNARDDB1BTKIRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448389-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4240743-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230083376-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS, INCORPORATED | 2023-03-16 | — | — | US | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230083376-A1 | BRM Targeting Compounds And Associated Methods Of Use | ADRM1, BRDT, RBX1 | CRBN 82/4885AR 938/4885DDB1 144/4885 |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | CRBN 82/4885AR 938/4885DDB1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.